Caris Life Sciences (CAI) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Caris Life Sciences

NasdaqGS•Healthcare•Biotechnology

$25.07-0.25(-0.01%)Market closed

Market Cap

$8.75B

P/E

3423.5x

P/S

7.9x

P/B

14.8x

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.

How this company scores

AverageMetricSide Score: 50/100

Strongest: Growth (16/25); weakest: Cash & Earnings Quality (9/25).

Profitability10/25

Growth16/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality9/25

Strengths

Rising earningsImproving leverageConsistent growthImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 3423.5x5y range 3423.5x – 3423.5x

P/S · 7.9x5y range 4.6x – 7.9x

P/B · 14.8x5y range 3.8x – 17.7x

Currently above its 5-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 4 quarters — monitor for earnings quality deterioration.

Price & Volume

Market Cap $8.75B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $1.11B
Q. Revenue: $263.71M
TTM EBITDA: $116.07M
TTM Op. Income: $95.31M
Q. Op. Income: $26.93M
TTM Net Income: $2.56M
Q. Net Income: $-637,000
EPS: $0
Shares Out.: $282.89M

$1.11B in TTM revenue grew from zero YoY, reaching $263.71M last quarter. TTM EBITDA of $116.07M and TTM operating income of $95.31M show growth is flowing through to the bottom line. TTM net income of $2.56M means revenue is converting into profit. Across the last 5 quarters, TTM revenue has risen for 2 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 12.7%
Op. Margin: 10.2%
Net Margin: -0.2%

Op. margin of 10.2% is up 20.1% YoY — cost efficiency is improving. Net margin at -0.2% Over the past year, operating margin is up 203% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 3423.5x
P/S Ratio: 7.9x
P/B Ratio: 14.8x

At 3423.5x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 7.9x and P/B of 14.8x provide additional context. Use the growth and margin sections to judge whether the multiple is justified.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $1.23B
Cash: N/A
Long-Term Debt: $392.97M
Book Value: $591.73M
D/E Ratio: 0.7
Debt/EBITDA: 11.7

With $1.23B in assets and $392.97M in long-term debt, D/E is 0.7and book value is $591.73M — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is down 19% — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $28.48M
TTM Free Cash Flow: $123.96M
FCF Margin: 11.2%
FCF / Net Income: 48.5

TTM FCF of $123.96M on $28.48M in operating cash flow. The FCF / Net Income ratio of 48.5x means free cash flow covers net income — earnings are backed by cash. Across the last 5 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.